The Journal of dermatological treatment最新文献

{"title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses.","authors":"Yunhong Zheng, Suju Luo","doi":"10.1080/09546634.2024.2449153","DOIUrl":"https://doi.org/10.1080/09546634.2024.2449153","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2449153"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.","authors":"Linda Stein Gold, James Del Rosso, Benjamin D Ehst, Matthew J Zirwas, Lawrence J Green, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Anna M Tallman","doi":"10.1080/09546634.2024.2444489","DOIUrl":"https://doi.org/10.1080/09546634.2024.2444489","url":null,"abstract":"<p><p><b>Background:</b> Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.<b>Methods:</b> Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability was evaluated using patient/parent/caregiver and investigator 5-point Local Tolerability Scales (LTS). Investigators assessed tolerability for sensitive skin areas, including face/neck.<b>Results:</b> 813 patients were randomized (∼80% pediatric). Mean pretreatment baseline overall LTS scores were similar across groups and trials: 1.0-1.9 (patient-assessed) indicating slight burning/stinging and itching; and 0.3-0.6 (investigator-assessed) indicating no-to-minimal irritation. Tapinarof was well tolerated with improvement from pretreatment baseline and no-to-minimal burning/stinging and itching from first application through Week 8 (patient-reported): mean Week 8 LTS scores were 0.2-0.4 (burning/stinging) and 0.6-0.8 (itching). Investigators reported improvement from pretreatment baseline with no-to-minimal irritation (dryness/erythema/peeling) from first Tapinarof application through Week 8 (mean LTS scores: 0.2 and 0.1 in ADORING 1 and 2, respectively). Across sensitive skin, investigators reported no-to-minimal irritation from first application through Week 8 (mean scores [Tapinarof versus vehicle]: 0-0.3 versus 0-1.0).<b>Conclusion:</b> Tapinarof was well tolerated locally from first application through Week 8, including on sensitive skin areas.</p><p><p><b>Clinicaltrials.gov numbers</b> NCT05014568, NCT05032859.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2444489"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143056176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis).","authors":"Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo G Carrera, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Francesca Gaiani, Francesco Loconsole, Angelo V Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi","doi":"10.1080/09546634.2025.2456532","DOIUrl":"https://doi.org/10.1080/09546634.2025.2456532","url":null,"abstract":"<p><p><b>Background:</b> Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.</p><p><p><b>Objective:</b> We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals.</p><p><p><b>Results:</b> Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2456532"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can pimozide kill parasites? Surprisingly, the most honest answer is 'yes'.","authors":"Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo","doi":"10.1080/09546634.2025.2466635","DOIUrl":"https://doi.org/10.1080/09546634.2025.2466635","url":null,"abstract":"<p><p><b>Purpose:</b> One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care.</p><p><p><b>Materials and methods:</b> A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024.</p><p><p><b>Results:</b> Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely <i>in vitro</i>, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment.</p><p><p><b>Conclusion:</b> With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2466635"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis.","authors":"Li Tingting, Peixin Zhang, Li Yang, Ruoyu Li, Ruojun Wang","doi":"10.1080/09546634.2025.2470379","DOIUrl":"https://doi.org/10.1080/09546634.2025.2470379","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to analyze the different therapeutic responses between topical antimicrobial-corticosteroid combination and topical corticosteroids alone on improving the skin microbiome and skin barrier of patients with atopic dermatitis (AD).</p><p><strong>Methods: </strong>Forty patients with mild-to-moderate AD were randomly assigned to receive two kinds of treatment. Skin swabs were collected from the lesional sites and nearby nonlesional sites at baseline, after topical medication treatment and 2 weeks post-treatment, and were analyzed by DNA sequencing of the fungal internal transcribed spacer (ITS)1-5 rDNA gene and the V3V4 region of the bacterial 16S rRNA gene.</p><p><strong>Results: </strong>According to our research analysis, both topical steroids alone and combination treatment of steroids and antimicrobials effectively improved the severity of AD and repaired skin barrier. AD lesions were characterized by a decreased sebum level, lower abundance of <i>Cutibacterium</i> and a higher abundance of <i>Staphylococcus</i>. A combined topical treatment with an antimicrobial and steroid showed better responses in increasing skin sebum level and restoring the skin bacterial microbiome, whereas topical steroid alone did not improve skin dysbiosis.</p><p><strong>Conclusion: </strong>A combined therapy with antimicrobial and steroid helps to recover the skin microbiome. Further studies are necessary to explore the therapeutic effects of treatments aiming at balancing the microbiome.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2470379"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).","authors":"D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli","doi":"10.1080/09546634.2025.2452948","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452948","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452948"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials.","authors":"Xinhong Su, Yushan Ou, Shifan Ruan, Xiaoqing Lv, Kun Qin, Jing Mao, Chao Ji","doi":"10.1080/09546634.2025.2474507","DOIUrl":"https://doi.org/10.1080/09546634.2025.2474507","url":null,"abstract":"<p><strong>Background: </strong>Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs).</p><p><strong>Objectives: </strong>To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs.</p><p><strong>Methods: </strong>PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study.</p><p><strong>Results: </strong>Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I²=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (<i>p</i> = .56) or medication (<i>p</i> = .69).</p><p><strong>Conclusions: </strong>This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2474507"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a skin management model based on a precision quantitative ointment dispenser on skin symptoms and quality of life in elderly psoriasis patients.","authors":"Jing Shen, Wei Zhou, Hui Zhang, Jiejun Jiang, Wei Dai","doi":"10.1080/09546634.2025.2474505","DOIUrl":"https://doi.org/10.1080/09546634.2025.2474505","url":null,"abstract":"<p><strong>Objective: </strong>This study explores the effects of a skin management model based on a precision quantitative ointment dispenser on skin symptoms and quality of life in elderly psoriasis patients.</p><p><strong>Methods: </strong>Elderly psoriasis patients adopted a skin management model based on a precision quantitative ointment dispenser. The Psoriasis Area and Severity Index (PASI) was measured prior to the intervention and at 2, 4, and 6 weeks post-intervention. The Chinese version of the Strategies Used by Patients to Promote Health (C-SUPPH), Symptom Checklist-90 (SCL-90), and Dermatology Life Quality Index (DLQI) were assessed at baseline and after 6 weeks. Patient satisfaction was measured following the 6-week intervention.</p><p><strong>Results: </strong>Both groups demonstrated reductions in PASI scores at 2, 4, and 6 weeks, with the observation group scoring lower (<i>p</i> < 0.05). After 6 weeks, all dimensions of the C-SUPPH showed improvements in both groups, with the observation group exhibiting greater enhancements; SCL-90 scores for anxiety and phobic anxiety reduced in the observation group; DLQI scores decreased in both groups, but the observation group reported superior outcomes; the observation group recorded a higher satisfaction rate (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The precision quantitative ointment dispenser-based skin management model improves skin symptoms and quality of life in elderly psoriasis patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2474505"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid improvement of kimura disease with dupilumab in a patient with suboptimal response to mepolizumab: a case report.","authors":"Meiying Tao, Tingting Gao, Lili Zhi, Naiqing Cao, Haotian Liu","doi":"10.1080/09546634.2025.2486668","DOIUrl":"https://doi.org/10.1080/09546634.2025.2486668","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2486668"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients.","authors":"Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li","doi":"10.1080/09546634.2025.2453597","DOIUrl":"https://doi.org/10.1080/09546634.2025.2453597","url":null,"abstract":"<p><strong>Background: </strong>Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the <i>ATP2C1</i> gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.</p><p><strong>Objective: </strong>To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.</p><p><strong>Methods: </strong>Two patients with biopsy-proven HHD received naloxone (2 mg/d, <i>via</i> intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.</p><p><strong>Results: </strong>Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.</p><p><strong>Conclusion: </strong>Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453597"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}